a cura del GISCoR
aggiornata a Novembre 2007
- EVIDENZE DI EFFICACIA
Bertario L, Russo A, Crosignani P, Sala P, Spinelli P, Pizzetti P, Andreola S, and Berrino F
Reducing colorectal cancer mortality by repeated faecal occult blood test: a nested case-control study.
Eur J Cancer, 35:973-7, 1999
Cotterchio M, Manno M, Klar N, McLaughlin J, Gallinger S.
Colorectal Screening is Associated with Reduced Colorectal Cancer Risk: A Case-Control Study within the Population-Based Ontario Familial Colorectal Cancer Registry.
Cancer Causes Control. 16(7):865-75, 2005
Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, Dassonville F, Bonithon-Kopp C.
Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study.
Gastroenterology 126(7):1674-80, 2004
Faivre J, Tazi MA, El Mrini T, Lejeune C, Benhamiche AM, Dassonville F
Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study.
Br J Cancer 79:680-3, 1999
Hewitson P, Glasziou P, Irwig L, Towler B, Watson E.
Screening for colorectal cancer using the faecal occult blood test, Hemoccult.
Cochrane Database Syst Rev. 2007 Jan 24;(1):
Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM
Randomised controlled trial of faecal occult blood screening for colorectal cancer.
Lancet 348:1472-7, 1996
Jorgensen OD, Kronborg O, Fenger C
A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds.
Gut. 50(1):29-32, 2002
Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C
Screening and rescreening for colorectal cancer: a controlled trial of fecal occult blood testing in 27,700 subjects.
Cancer 62:645-651, 1988
Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sandergaard O
Randomised study of screening for colorectal cancer with faecal occult blood test.
Lancet 348 :1467-71, 1996
Lazovich D, Weiss NS, Stevens NG, White E, Mc Knight B, Wagner EH
A case-control study to evaluate efficacy of screening for faecal occult blood.
J Med Screen 2 : 84-9, 1995
Mandel JS, Bond JH, Church TR, SnoverDC, Bradley GM, Schuman LM, and Ederer F
Reducing mortality from colorectal cancer by screening for faecal occult blood.
N Eng J Med 328: 1365-71, 1993
Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM
The effect of fecal occult-blood screening on the incidence of colorectal cancer
N Engl J Med 343:1603-7, 2000
Mandel JS, Church TR, Ederer F, Bond JH
Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
J Natl Cancer Inst 3;91(5):434-7, 1999
Nakajima M, Saito H, Soma Y, Sobue T, Tanaka M, Munakata
A Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case-control study.
Br J Cancer 7;89(1):23-8, 2003
Saito H, Soma Y, Koeda J, Wada T, Kawaguchi H, Sobue T, Aisawa T, and Yoshida Y
Reduction in risk of mortality by fecal occult blood screening with immunochemical hemagglutination test.
A case- control study. Int J Cancer 61: 465-9, 1995
Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD
Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial.
Gut 50(6):840-4, 2002
Selby JV, Friedman G.D., Quesenberry C.P., and Weiss N.S
Effect of fecal occult blood testing on mortality from colorectal cancer. A case-control study.
Ann Intern Med 118:1-6, 1993
Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J. Screening for colorectal cancer using the faecal occult blood test, hemoccult.
Cochrane Database Syst Rev (2): CD001216, 2000
Wahrendorf J, Robra B.P., Wiebelt H., Oberhausen R., Weiland M., Dhom G
Effectiveness of colorectal cancer screening: result from a population-based case-control evaluation in Saarland, Germany.
Eur J Cancer Prev 2: 221-7, 1993
Zappa M, Castiglione G, Grazzini G, Falini P, Giorgi D, Paci E, Ciatto S.
Effect of faecal occult blood testing on colorectal mortality: results of a population-based case-control study in the district of Florence, Italy. Int J Cancer. 1997 Oct 9;73(2):208-10.
Zappa M, Castiglione G, Paci E, Grazzini G, Rubeca T, Turco P, Crocetti E, Ciatto S.
Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience.
Int J Cancer. 2001 Apr 1;92(1):151-4.
- EVIDENZE DI EFFICACIA
Atkin WS, Cuzik, Northover JMA, Whynes DK.
Prevention of colorectal cancer by once only sigmoidoscopy.
Lancet 341: 736-740, 1993
Atkin WS, Crook CF, Cuzick J, et al.
Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial.
Lancet 359: 1291–1300, 2002
Farraye FA, Wallace M.
Clinical significance of small polyps found during screening with flexible sigmoidoscopy.
Gastrointest Endosc Clin N Am 12(1):41-51, 2002
Levin TR.
Flexible sigmoidoscopy for colorectal cancer screening: valid approach or short-sighted?
Gastroenterol Clin North Am 31(4):1015-1029, 2002
Levin TR, Palitz AM.
Flexible sigmoidoscopy: an important screening option for average-risk individuals.
Gastrointest Endosc Clin N Am 12(1): 23-40, 2002
Levin TR, Farraye FA, Schoen RE, Hoff G, Atkin W, Bond JH, Winawer S, Burt RW, Johnson DA, Kirk LM, Litin SC. Rex
Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group.
Gut 54(6):807-813, 2005
Lewis JD, Ng K, Hung KE, Bilker WB, Berlin JA, Brensinger C, Rustgi AK.
Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy.
Arch Intern Med 163(4): 413-420, 2003
Newcomb PA, Norfleet RG, Storer BE, Surawicz T, Marcus PM.
Screening sigmoidoscopy and colorectal cancer mortality.
J Natl Cancer Inst 84: 1572–1575, 1992
Ransohoff DF.
Lessons from the UK sigmoidoscopy screening trial.
Lancet 359(9314):1266-1267, 2002
Painter J, Saunders DB, Bell GD, Williams CB, Pitt R, Bladen J.
Depth of insertion at flexible sigmoidoscopy: implications for colorectal cancer screening and instrument design.
Endoscopy 31: 227-231, 1999
Scholefield JH, Moss S.
Screening sigmoidoscopy for colorectal cancer.
Lancet 362(9391): 1167-1168, 2003
Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, Ferraris R, Gasperoni S, Penna A, Risio M, Rossini FP, Sciallero S, Zappa M, Atkin WS. SCORE Working Group-Italy.
Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"-SCORE.
J Natl Cancer Inst 94: 1763-1772, 2002
Senore C, Segnan N, Rossini FP, Ferraris R, Cavallero M, Coppola F, Pennazio M, Atkin WS.
Screening for colorectal cancer by once only sigmoidoscopy: a feasibility study in Turin, Italy.
J Med Screen 3(2):72-78, 1996
Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS.
A case control study of screening sigmoidoscopy and mortality from colorectal cancer.
N Engl J Med 326: 653–657, 1992
Senore C, Segnan N, Bonelli L, Sciallero S, Pennazio M, Angioli D, Crosta C, Gasperoni S, Malfitana G; SCORE Working Group.
Predicting proximal advanced neoplasms at screening sigmoidoscopy.
Dis Colon Rectum. 47(8):1331-1340, 2004
Zauber AG.
Quality control for flexible sigmoidoscopy: which polyps count?
Gastroenterology 126(5): 1474-1477, 2004
Allison JE, Lawson M.
Screening tests for colorectal cancer: a menu of options remains relevant.
Curr Oncol Rep. 2006 Nov;8(6):492-8. Review
Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV.
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70
Allison JE, Tekawa IS, Ransom LJ, Adrain AL.
A comparison of fecal occult-blood tests for colorectal-cancer screening.
N Engl J Med. 1996 Jan 18;334(3):155-9.
Berry DP, Clarke P, Hardcastle JD, Vellacott KD.
Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening.
Br J Surg 84: 1274–1276, 1997
Castiglione G, Grazzini G, Ciatto S.
Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.
Br J Cancer 65:942-944, 1992
Castiglione G, Grazzini G, Miccinesi G, Rubeca T, Sani C, Turco P, Zappa M.
Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood.
J Med Screen. 2002;9(3):99-103.
Castiglione G, Visioli CB, Ciatto S, Grazzini G, Bonanomi AG, Rubeca T, Mantellini P, Zappa M.
Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.
Br J Cancer. 2007 Jun 4;96(11):1750-4
Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P, Ciatto S.
Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer.
Br J Cancer. 1996
Castiglione G, Zappa M, Grazzini G, Rubeca T, Turco P, Sani C, Ciatto S.
Screening for colorectal cancer by faecal occult blood test: comparison of immunochemical tests.
J Med Screen. 2000;7(1):35-7.
Castiglione G, Zappa M, Grazzini G, Sani C, Mazzotta A, Mantellini P, Ciatto S.
Cost analysis in a population-based screening programme for colorectal cancer: comparison of immunochemical and guaiac faecal occult blood testing.
J Med Screen 4:142-46, 1997
Church TR.
Fecal occult blood screening in the Minnesota Study: sensitivity of the screening test.
J Natl Canc Inst 89:1440-8, 1997
Fletcher RH.
Rationale for combining different screening strategies.
Gastrointest Endosc Clin N Am 12(1): 53-63, 2002
Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, Sadowski D, Sudduth R, Zuckerman GR, Rockey DC. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.
Am J Gastroenterol 95(5):1331-8, 2000
Hope RL, Chu G, Hope AH, Newcombe RG, GillespiePE, Williams SJ.
Comparison of three faecal occult blood tests in the detection of colorectal neoplasia.
Gut 39(5):722-5, 1996
Iwase T
The evaluation of an immunochemical occult blood test by reversed passive haemoagglutination compared with Hemoccult II in screening for colorectal cancer .
In “Fecal Occult blodd tests: Current issues and New tests” ed. G.P. Young and H Saito, pag. 90-95 (1992), Smith Kline Diagnostics Inc., San Josè
Jahn H, Joergensen OD, Kronborg O, Fenger C. Can
Hemoccult-II replace colonoscopy in surveillance after radical surgery for colorectal cancer and after polypectomy?
Dis Colon Rectum 35(3):253-6, 1992
Jouve JL, Remontet L, Dancourt V, Lejeune C, Benhamiche AM, Faivre J, Esteve J.
Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening
Br J Cancer 84(11):1477-81, 2001
Lang CA, Ransohoff DF.
On the sensitivity of faecal occult blood test screening for colorectal cancer
J Natl Canc Inst 89:1392-3, 1997
Launoy G, Smith TC, Duffy SW and Bouvier V.
Colorectal cancer mass screening: estimate of faecal occult blood test sensitivity taking into account cancer mean sojourn time
Int J Cancer 73:220-24, 1997
Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y.
A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
Ann Intern Med. 146(4):244-55, 2007
Lieberman DA, Weiss DG;
Veterans Affairs Cooperative Study Group 380. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
N Engl J Med 345(8): 555-560, 2001
Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y.
A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.
Gastroenterology 129(2):422-8, 2005
Moss SM, Hardcastle JD, Coleman DA, Robinson MH, Rodrigues VC
Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test
Int J Epidemiol 28(3):386-90, 1999
Nakama H, Fattah A, Zhang B, Uehara Y, Wang C.
A comparative study of immunochemical fecal tests for detection of colorectal adenomatous polyps.
Hepatogastroenterology 47(32):386-9, 2000
Nakama H, Yamamoto M, Kamijo N, Li T, Wei N, Fattah AS, Zhang B.
Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia.
Hepatogastroenterology 46(25):228-31, 1999
Nakama H, Zhang B, Fattah AS.
A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer.
Eur J Cancer. 2000 Mar;36(5):647-50
Nicholson FB, Korman MG.
Acceptance of flexible sigmoidoscopy and colonoscopy for screening and surveillance in colorectal cancer prevention. J Med Screen 12(2): 89-95, 2005
Petrelli N, Michalek AM, Freedman A, Baroni M and Rodriguez-Bigas M.
Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program.
Surg Oncol 3: 27-36, 1993
Rasmussen M, Fenger C, Kronborg O.
Diagnostic yield in a biennial Hemoccult-II screening program compared to a once-only screening with flexible sigmoidoscopy and Hemoccult-II.
Scand J Gastroenterol 38(1):114-8, 2003
Rasmussen M, Kronborg O, Fenger C, Jorgensen OD.
Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study.
Scand J Gastroenterol 34(1):73-8, 1999
Robinson MH, Kronborg O, Williams CB, Bostock K, Rooney PS, Hunt LM and Hardcastle JD.
Fecal occult blood testing and colonoscopy in the surveillance of subjects at high risk of colorectal neoplasia.
Br J Surg 82, 318-320. 1995
Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD.
Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests.
Br J Surg 81(3):448-51, 1994
Rubeca T, Rapi S, Confortini M, Brogioni M, Grazzini G, Zappa M, Puliti D, Castiglione G, Ciatto S.
Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series.
Int J Biol Markers. 2006 Jul-Sep;21(3):157-61. Erratum in: Int J Biol Markers. 2007 Jan-Mar;22(1):86.
Saito H, Soma Y, Nakajima M, Koeda J, Kawaguchi H, Kakizaki R, Chiba R, Aisawa T, Munakata A
A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test.
Oncol Rep 7(4):815-9, 2000
Saito H.
Screening for colorectal cancer by immunochemical fecal occult blood testing.
Jpn J Cancer Rev 87:1011-24, 1996
Saitoh O, Kojima K, Kayazawa M, Sugi K, Tanaka S, Nakagawa K, Teranishi T, Matsuse R, Uchida K, Morikawa H, Hirata I, Katsu K.
Comparison of tests for fecal lactoferrin and fecal occult blood for colorectal diseases: a prospective pilot study.
Intern Med 39(10):778-82, 2000
Segnan N, Senore C, Andreoni B, Arrigoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, DiPlacido R, Ferrari A, Ferraris R, Ferrero F, Fracchia M, Gasperoni S, Malfitana G, Recchia S, Risio M, Rizzetto M, Saracco G, Spandre M, Turco D, Turco P, Zappa M; SCORE2 Working Group-Italy.
Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
J Natl Cancer Inst 97(5):347-57, 2005
Segnan N, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, Ederle A, Fantin A, Ferrari A, Fracchia M, Ferrero F, Gasperoni S, Recchia S, Risio M, Rubeca T, Saracco G, Zappa M; SCORE3 Working Group-Italy.
Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening.
Gastroenterology 132(7):2304-12, 2007
St. John DJ, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, and Penfold JCB.
Evaluation of new occult blood tests for detection of colorectal neoplasia.
Gastroenterology 104:1661-8, 1993
Tazi MA, Faivre J, Lejeune C, Bolard P, Phelip JM, Benhamiche AM.
Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test.
Eur J Cancer Prev 8(2):131-5, 1999
Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, Niv Y.
Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
Am J Gastroenterol 100(11):2519-25, 2005
Yamamoto M, Nakama H.
Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods.
Hepatogastroenterology 7(32):396-9, 2000
Young GP.
Screening for colorectal cancer: alternative faecal occult blood tests.
Eur J Gastroenterol Hepatol. 10(3):205-12, 1998
Zappa M, Castiglione G, Paci E, Grazzini G, Rubeca T, Turco P, Crocetti E, Ciatto S.
Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience.
Int J Cancer 92(1):151-4, 2001
- VALUTAZIONI COSTO-EFFICACIA
Hassan C, Zullo A, Laghi A, Reitano I, Taggi F, Cerro P, Iafrate F, Giustini M, Winn S, Morini S.
Colon cancer prevention in Italy: cost-effectiveness analysis with CT colonography and endoscopy.
Dig Liver Dis. 39(3):242-50, 2007
Inadomi JM.
Update on the cost-effectiveness of screening for colorectal neoplasia.
Curr Opin Gastroenterol 19(1):44-50, 2003
Lin OS, Kozarek RA, Schembre DB, Ayub K, Gluck M, Cantone N, Soon MS, Dominitz JA.
Risk stratification for colon neoplasia: screening strategies using colonoscopy and computerized tomographic colonography.
Gastroenterology. 2006 Oct;131(4):1011-9
Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R.
Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer.
Gastroenterology 125(6): 1645-1650, 2003
Pignone M, Saha S, Hoerger T, Mandelblatt J.
Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force.
Ann Intern Med. 16;137(2):96-104, 2002
Sonnenberg A.
Cost-effectiveness in the prevention of colorectal cancer.
Gastroenterol Clin North Am 31(4): 1069-1091, 2002
Ransohoff DF.
Screening colonoscopy in balance. Issues of implementation.
Gastroenterol Clin North Am 31(4): 1031-1044, 2002
Sonnenberg A, Delco F, Inadomi JM.
Cost-effectiveness of colonoscopy in screening for colorectal cancer.
Ann Intern Med 133(8): 573-584, 2000
Lieberman D.
Cost-effectiveness model for colon cancer screening.
Gastroenterology 109: 1781-1790, 1995
Whynes DK; Nottingham FOB Screening Trial.
Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
J Med Screen. 2004
- ESPERIENZE DI SCREENING
Alexander F, Weller D.
UK CRC screening pilot evaluation team Evaluation of the UK colorectal cancer screening Pilot - Final Report, Report Supplement
Crotta S, Castiglione G, Grazzini G, Valle F, Mosconi S, Rosset R.
Feasibility study of colorectal cancer screening by immunochemical faecal occult blood testing: results in a northern Italian community.
Eur J Gastroenterol Hepatol. 2004 Jan;16(1):33-7.
Garvican L
Planning for a possible national colorectal cancer screening programme.
J Med Screen, 5:187-94, 1998
Gnauck R
Screening for colon cancer in Germany.
Tumori 81 Suppl.:30-7, 1995
Grazzini G, Castiglione G, Ciabattoni C, Franceschini F, Giorgi D, Gozzi S, Mantellini P, Lopane P, Perco M, Rubeca T, Salvadori P, Visioli CB, Zappa M.
Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results.
Eur J Cancer Prev 13(1):19-26, 2004
Grazzini G, Castiglione G, Isu A, Mantellini P, Rubeca T, Sani C, Turco P, Zappa M.
Colorectal cancer screening by fecal occult blood testing: results of a population-based experience.
Tumori. 2000 Sep-Oct;86(5):384-8.
Grazzini G, Visioli CB, Ventura L, Castiglione G, Rubeca T, Zappa M.
I programmi di screening colorettale in Toscana. I risultati dell’anno 2004 e le criticità,
in “I programmi di screening della Regione Toscana – 6° rapporto annuale - Risultati e attività di ricerca (dati 2004)”, pag. 33-45, 2005
Niv Y.
Screening the average risk population for colorectal cancer: the Israeli experience 1985-97.
Colorectal Dis. 5(4):358-61, 2003
Pedersen KE, Elwood M.
Current international developments in population screening for colorectal cancer.
ANZ J Surg 72(7):507-12, 2002
Rozen P
Colorectal cancer screening in Israel
Gastrointestinal Endoscopy, 47(1): 97-100, 1998
Saito H, Yoshida Y.
Mass screening: Japanese perspective. In “Prevention and early detection of colorectal cancer”
Edited Young GP, Rozen P, Levin B. 301-11, W.B. Saunders Company L.T.D., London, 1996
Saito H.
Screening for colorectal cancer: current status in Japan.
Dis Colon Rectum 43(10 Suppl):S78-84, 2000
Steele RJ, Parker R, Patnick J, Warner J, Fraser C, Mowat NA, Wilson J, Alexander FE, Paterson JG; United Kingdom Colorectal Screening Pilot Group.
A demonstration pilot trial for colorectal cancer screening in the United Kingdom: a new concept in the introduction of healthcare strategies.
J Med Screen.8(4):197-202, 2001
Zambelli A., Lupinacci G, Alquari P, Bianchi G, Bodini P, Boldori L, Buffoni F, Buscarini E, Filippini L, Longinotti E, Mantovani M, Sabadini D.
Screening for colorectal cancer in Cremona province: preliminary results.
Digestive and Liver Disease Vol 36 Suppl 2, 324, 2004
Arbyn M, Van Oyen H, Lynge E, Micksche M, Faivre J, Jordan J.
European Commission's proposal for a council recommendation on cancer screening.
BMJ 327(7409):289-90, 2003
Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Provincie autonome di Trento e Bolzano. Accordo tra il Ministero della sanità e le Regioni e Provincie Autonome di Trento e Bolzano sulle linee-guida concernenti la prevenzione, la diagnostica e l’assistenza in oncologia. Gazzetta Ufficiale della Repubblica Italiana 100:52-7, 2001
European Group for Colorectal Cancer Screening (1999).
Recommendation to include colorectal cancer screening in public health policy.
J Med Screen 6:80-1, 1999
Levin B, Brooks D, Smith RA, Stone A
Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers.
CA Cancer J Clin 53(1):44-55, 2003
McLeod, R., with the Canadian Task Force on Preventive Health Care.
Screening Strategies for Colorectal Cancer: Systematic Review & Recommendations. CTFPHC Technical Report #01-2. February, 2001. London, ON: Canadian Task Force.
National Health and Medical Research Council NHMRC - The prevention, early detection and management of colorectal cancer March 1999 Ed. Biotext, Canberra
Raccomandazioni del Consiglio Europeo del 2 dicembre 2003 sullo screening dei tumori. Gazzetta Ufficiale dell’Unione Europea del 16/12/2003
Raccomandazioni per la pianificazione e l’esecuzione degli screening di popolazione per la prevenzione del cancro della mammella, del cancro della cervice uterina e del cancro del colon rettoMinistero della Salute, novembre 2006
Scottish Intercollegiate Guidelines Network Management of colorectal cancer A national clinical guideline March 2003
Smith RA, Cokkinides V, Eyre HJ
American Cancer Society Guidelines for Early Detection of Cancer
CA Cancer J Clin 54:41-52, 2004
Smith RA, Cokkinides V, Eyre HJ.
American Cancer Society guidelines for the early detection of cancer, 2006.
CA Cancer J Clin. 56(1):11-25, 2006
Winawer SJ, Fletcher Rh, Rex D, Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C.
Colorectal cancer screening: clinical guidelines and rationale. Update based on new evidence.
Gastroenterology 124:544-60, 2003
Working Party on screening for colorectal cancer Population Screening for colorectal cancer published by National Advisory Committee on Health and Disability, 1998
Young GP, St John DJ, Winawer SJ, Rozen P WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy report).
Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy).
Am J Gastroenterol 97(10):2499-507, 2002